[Breaking] Central Pharmaceutical Review Board: "AstraZeneca shows no safety issues in elderly yet... but low numbers mean statistical efficacy verification is pending"
![[Breaking] Central Pharmaceutical Review Board: "AstraZeneca shows no safety issues in elderly yet... but low numbers mean statistical efficacy verification is pending"](http://www.asiae.co.kr/news/img_view.htm?img=2020120409454047289_1607042740.png)
[Asia Economy Reporter Lee Chunhee]
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
